Information on Humira the Brand Name Form of Adalimumab
Humira, the brand name form of adalimumab,is a prescription mediion used to treat certain kinds of arthritis, ankylosing spondylitis,Crohn's disease, plaque psoriasis, and ulcerative colitisadults and chilen. Humira belongsto a group of ugs called tumor necrosis factor blockers, which help reduce inflammation.This mediion comesan injectable form and is injected just under the skin usuallyonce every other week. Common side effects of Humira include reaction at the injectionsite, sinus infections, and headaches.
Psoriatic arthritis adalimumab antibodies psoriatic arthritis
Why do some people treated for psoriatic arthritisstop responding to their treatmenté Find out next.Study Confirms High Prevalence of ADAAdalimumabTreated Psoriasis Graeme M. Lipper, writingMedscape described a recent study that might shed lighton why some treatments for psoriatic arthritis may fail over time.Menting, Lumig, DeVries and colleagues published the results of a recent study entitledExtent and Consequences of Antibody Formation Against AdalimumabPatients With Psoriasis:OneYear Followup Adalimumab, a humanized monoclonal antibody(IgG1) that binds to and inactivates the proinflammatory
cytokine tumor necrosis factor alpha, is ahighly effective treatment for moderate to severe psoriatic arthritis. Unfortunately,this ug may induce antiug antibodies (ADAs)almost one half of patients taking adalimumablongterm, and prior studies show that ADAs contribute to disease relapse and waning therapeuticresponse to adalimumab and other biologic therapies.In their study they found that 49 % of patients developed ADAs, with the vast majority (90%)forming antibody titers within the first 24 weeks of therapy.Comment: Interesting and answers a lot of questions about failing therapy.